Ethisterone CAS 434-03-7 Female Sex Hormones Pregneninolone
Place of Origin:ShenZhen, China (Mainland)
Type:Anesthetic Agents, Antineoplastic Agents, Blood System Agents, Endocrine System Agents, Vitamins, Amino Acids and Coenzymes
Grade Standard:Medicine Grade
Purity:99%min, 99% Ethisterone
Appearance:White Powder Ethisterone
Application:Pharmaceutical Raw Intermediates
Payment Term:T/T;Western Union;Trade Assurance
Ethisterone is a metabolite of danazol. Ethisterone is a progestogen hormone. The first orally active progestin, ethisterone (pregneninolone, 17α-ethynyltestosterone or 19–norandrostane), It is a progestin medication which was used in the treatment of gynecological disorders but is now no longer available. It was used alone and was not formulated in combination with an estrogen.
Ethisterone is a progestogen hormone.
The first orally active progestin, ethisterone (pregneninolone, 17α-ethynyltestosterone or 19–norandrostane), the 17α-ethynyl analog of testosterone, was synthesized in 1938 by Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, and Arthur Serini at Schering AG in Berlin and marketed in Germany in 1939 as Proluton C and by Schering in the U.S. in 1945 as Pranone.
Ethisterone was also marketed in the U.S. from the 1950s into the 1960s under a variety of trade names by other pharmaceutical companies that had been members of the pre-World War II European hormone cartel (Ciba, Organon, Roussel).
Ethisterone, also known as ethinyltestosterone, pregneninolone, and anhydrohydroxyprogesterone and formerly sold under the brand names Proluton C and Pranone among others, is a progestin medication which was used in the treatment of gynecological disorders but is now no longer available. It was used alone and was not formulated in combination with an estrogen. The medication is taken by mouth.
Side effects of ethisterone include masculinization among others. Ethisterone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some androgenic and anabolic activity and no other important hormonal activity.
Ethisterone was discovered in 1938 and was introduced for medical use in Germany in 1939 and in the United States in 1945. It was the second progestogen to be marketed, following injected progesterone in 1934, and was both the first orally active progestogen and the first progestin to be introduced. Ethisterone was followed by the much more widely used and known progestin norethisterone in 1957.
Ethisterone is a progestogen, or an agonist of the progesterone receptors (PRs). It is described as a relatively weak progestogen, similarly to its analogue dimethisterone. Ethisterone has about 20-fold lower potency as a progestogen relative to norethisterone.
Based on in vitro research, ethisterone and norethisterone are about equipotent in their EC50 values for the androgen receptor (AR), whereas, conversely, norethisterone shows markedly increased potency relative to ethisterone in terms of its EC50 for the progesterone receptor (PR). As such, there is a considerable separation in the ratios of androgenic and progestogenic activity for ethisterone and norethisterone.Moreover, at the larger dosages in which it is used to achieve equivalent progestogenic effect, ethisterone has marked androgenic effects relative to norethisterone and other 19-nortestosterone progestins, and this has limited its clinical use. Due to its androgenic activity, ethisterone has been associated with the masculinization of female fetuses in women who have taken it during pregnancy.The 5α-reduced metabolite of ethisterone shows considerably increased affinity for the AR (Ki = 16.1 nM for 5α-dihydroethisterone and 101.1 nM for ethisterone).
Testosterone is aromatized into estradiol, and norethisterone, the 19-nortestosterone analogue of ethisterone, has similarly been shown to be aromatized into ethinylestradiol. In accordance, high dosages of norethisterone have been found to be associated with high rates of estrogenic side effects such as breast enlargement in women and gynecomastia in men, as well as with improvement of menopausal symptoms in postmenopausal women. In contrast, ethisterone and other progestogens such as progesterone and hydroxyprogesterone caproate were not associated with such effects, suggesting that they have little or no estrogenic activity. Similarly, although ethisterone showed estrogenic effects in the uterus and vagina in rats, few or no such effects were observed in women treated with the medication, even at very high doses. As such, ethisterone does not appear to share the estrogenic activity of norethisterone, at least in humans.
Ethisterone has relatively high affinity for sex hormone-binding globulin, about 14% of that of dihydrotestosterone and 49% of that of testosterone in one study.